BLAINJECTIONINJECTABLE
Approved
May 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YUFLYMA (adalimumab-aaty) is a TNF-alpha inhibitor monoclonal antibody approved by the FDA in May 2023 as a biosimilar to reference adalimumab (HUMIRA). It blocks TNF-alpha interaction with p55 and p75 cell surface receptors, reducing inflammation and joint destruction across multiple autoimmune and inflammatory conditions.
Growth
Early-stage biosimilar in growth phase with opportunity for rapid team expansion if pricing and uptake accelerate in a crowded TNF-inhibitor market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Yuflyma® (Adalimumab), Patient Experience After Switching
Started Jun 2022
300 enrolled
Rheumatoid ArthritisAnkylosing SpondylarthritisAxial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis+3 more
Career Relevance
YUFLYMA represents a growth-stage biosimilar opportunity in a maturing, highly competitive market where success depends on health economics, payer relationships, and clinical differentiation rather than clinical innovation. Roles will focus on market share capture, formulary positioning, and cost-justification against established TNF inhibitors and novel mechanisms.
Brand Manager
Worked on YUFLYMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.